ST elevation myocardial infarction analgesic therapy

Acute Coronary Syndrome Main Page
ST Elevation Myocardial Infarction Microchapters
Home
Patient Information
Overview
Pathophysiology
Pathophysiology of Vessel Occlusion
Pathophysiology of Reperfusion
Gross Pathology
Histopathology
Causes
Differentiating ST elevation myocardial infarction from other Diseases
Epidemiology and Demographics
Risk Factors
Triggers
Natural History and Complications
Risk Stratification and Prognosis
Pregnancy
Diagnosis
Diagnostic Criteria
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
EKG Examples
Chest X Ray
Cardiac MRI
Echocardiography
Coronary Angiography
Treatment
Pre-Hospital Care
Initial Care Oxygen Nitrates Analgesics Aspirin Beta Blockers Antithrombins The coronary care unit The step down unit STEMI and Out-of-Hospital Cardiac Arrest Pharmacologic Reperfusion Reperfusion Therapy (Overview of Fibrinolysis and Primary PCI) Fibrinolysis Reperfusion at a Non–PCI-Capable Hospital:Recommendations Mechanical Reperfusion The importance of reducing Door-to-Balloon times Primary PCI Adjunctive and Rescue PCI Rescue PCI Facilitated PCI Adjunctive PCI CABG Management of Patients Who Were Not Reperfused Assessing Success of Reperfusion Antithrombin Therapy Antithrombin therapy Unfractionated heparin Low Molecular Weight Heparinoid Therapy Direct Thrombin Inhibitor Therapy Factor Xa Inhibition DVT prophylaxis Long term anticoagulation Antiplatelet Agents Aspirin Thienopyridine Therapy Glycoprotein IIbIIIa Inhibition Other Initial Therapy Inhibition of the Renin-Angiotensin-Aldosterone System Magnesium Therapy Glucose Control Calcium Channel Blocker Therapy Lipid Management
Pre-Discharge Care
Recommendations for Perioperative Management–Timing of Elective Noncardiac Surgery in Patients Treated With PCI and DAPT
Post Hospitalization Plan of Care
Long-Term Medical Therapy and Secondary Prevention Overview Inhibition of the Renin-Angiotensin-Aldosterone System Cardiac Rehabilitation Pacemaker Implantation Long Term Anticoagulation Implantable Cardioverter Defibrillator ICD implantation within 40 days of myocardial infarction ICD within 90 days of revascularization
Case Studies
Case #1
Case #2
Case #3
Case #4
Case #5
ST elevation myocardial infarction analgesic therapy On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on ST elevation myocardial infarction analgesic therapy
CDC on ST elevation myocardial infarction analgesic therapy
ST elevation myocardial infarction analgesic therapy in the news
Blogs on ST elevation myocardial infarction analgesic therapy
Directions to Hospitals Treating ST elevation myocardial infarction
Risk calculators and risk factors for ST elevation myocardial infarction analgesic therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor: Cafer Zorkun, M.D., Ph.D. [2]

Overview

Although, the recommendation for morphine induced pain relief has been reduced to a Class IIa recommendation for patient with unstable angina pectoris (UA) and Non ST Elevation Myocardial Infarction (NSTEMI), the use of opiate analgesics (e.g. morphine) remains a Class I recommendation for patients with STEMI.

Analgesic Agents that are Contraindicated in STEMI

In contrast to morphine and aspirin, cyclooxygenase-2 (COX-2) inhibitors and other non steroidal anti inflammatory drugs should be discontinued immediately in the setting of STEMI in so far as they inhibit aspirin and because they have been associated with an increased risk of cardiovascular events. Non-steroidal anti-inflammatory drugs (NSAIDs) bind to a serine residue and thereby block aspirin's access cyclooxygenase-1, through interference with the prostaglanin system they may worsen hypertension or congestive heart failure. In a non-randomized analysis from the EXTRACT trial, administration of a NSAID within 7 days of enrollment was associated with a higher incidence of 30-day death or nonfatal recurrent MI (15.9% vs. 10.8%, p < 0.001).

Morphine

Mechanism of Benefit of Morphine Sulfate

The mechanisms of benefit of morphine sulfate include the following:

• Reduction in the hyperadrenergic state which in turn:
  • Reduces the pulse and thereby reduces oxygen consumption
  • Reduces the systolic blood pressure (afterload) and thereby reduces cardiac workload
  • Increases the threshold for ventricular fibrillation
  • Reduces metabolic demands and therefore cardiac workload
  • Reduces the work of breathing
• Reduces preload and pulmonary capillary wedge pressure

Clinical Trial Data Supporting Morphine Administration

While there is no large scale clinical trial data demonstrating an improvement in mortality or other hard clinical endpoints associated with analgesic administration, analgesic agents do relieve anxiety and apprehension, both of which can heighten pain perception. Morphine may reduce the pulmonary capillary wedge pressure and make breathing easier improving the patient's quality of life.

Dosing of Morphine

Morphine sulfate (2 to 4 mg IV with increments of 2 to 8 mg IV repeated at 5- to 15-minute intervals)

Side Effects of Morphine

Adverse effects can be seen in patients with morphine sensitivity.

• Hypotension: Hypotension can be minimized by keeping the patient supine. If the systolic blood pressure drops below 100 mm Hg, then the lower extremities can be elevated.

• Vagomimetic Effects such as bradycardia: Morphine can heighten vagal tone, and administration of a vagolytic agent such as intravenous atropine in doses of 0.5- to 1.5-mg doses intravenously may be helpful in reducing the excessive vagomimetic effects of morphine. The administration of atropine should be reserved for those patients in whom bradycardia or hypotension are present.

• Respiratory depression: Respiratory rate and depth should be monitored. The narcotic reversing agent naloxone, 0.1 to 0.2 mg intravenously, can be given initially if indicated and repeated after 15 minutes if necessary.

• Nausea and Vomiting: May be treated with phenothiazines.

2007 Focused Update of the 2004 ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (DO NOT EDIT)

Class I

"1. Morphine sulfate (2 to 4 mg IV with increments of 2 to 8 mg IV repeated at 5- to 15-minute intervals) is the analgesic of choice for management of pain associated with STEMI. (Level of Evidence: C)"

"2. Patients routinely taking NSAIDs (except for aspirin), both nonselective as well as COX-2 selective agents, before STEMI should have those agents discontinued at the time of presentation with STEMI because of the increased risk of mortality, reinfarction, hypertension, heart failure, and myocardial rupture associated with their use. (Level of Evidence: C)"

Class III (Harm)

"1. NSAIDs (except for aspirin), both nonselective as well as COX-2 selective agents, should not be administered during hospitalization for STEMI because of the increased risk of mortality, reinfarction, hypertension, heart failure, and myocardial rupture associated with their use. (Level of Evidence: C)"

Sources

• The 2004 ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction

• The 2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients with ST-Elevation Myocardial Infarction

References

Template:WikiDoc Sources